Skip to main content
Caplight Logo









Aigen Sciences

Aigen Sciences

Private
SeoulHealthcare & Life Scienceshttps://aigensciences.com/

Last Round

Series A

Oct 16, 2024

Total Funding Raised

$11.74M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Aigen Sciences is a biotechnology company that provides an AI-driven drug discovery platform to develop small-molecule synthetic drugs for intractable diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

drug discoveryAI drug discoverysmall-molecule therapeuticsgenerative AItranscriptome dataoncology researchlarge language modelsLLMin silico drug designADMET modelingbiotech R&Dprecision medicineAI-first biotechdrug pipelinecomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aigen Sciences Comparables

Compare Aigen Sciences with similar companies based on industry and business-model similarity.

Aigen Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HITS Inc.
88%
PharmCADD Co., Ltd.
88%
DR.NOAH Biotech
83%

Aigen Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 16, 2024
Pre SeedOct 5, 2022

Key People

Founding team and executive leadership

Soojung Lee

Chief Operating Officer

Executive Team

Aigen Sciences Investors

Notable investors and investment history

Aigen Sciences investors
InvestorRounds
Korea University HoldingsPre Seed
K2 Investment PartnersSeries A
Bluepoint PartnersPre Seed
Premier PartnersSeries A
QUAD Investment ManagementSeries A
Medytox Venture InvestmentPre Seed, Series A
Partners InvestmentPre Seed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Grew 33% QoQ, from 12 to 16 employees.

  • Apr 19, 2026

    Grew 25% QoQ, from 12 to 15 employees.

Aigen Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aigen Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aigen Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul
Employee Range14
Year Founded2021
Last FundingOct 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?